

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	3591604
<b>Application Number:</b>	10809635
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	8938
<b>Title of Invention:</b>	DIPEPTIDYL PEPTIDASE INHIBITORS
<b>First Named Inventor/Applicant Name:</b>	Jun Feng
<b>Customer Number:</b>	32793
<b>Filer:</b>	David J. Weitz/Matt Russell
<b>Filer Authorized By:</b>	David J. Weitz
<b>Attorney Docket Number:</b>	DPP-IV-5004-U
<b>Receipt Date:</b>	09-JUL-2008
<b>Filing Date:</b>	24-MAR-2004
<b>Time Stamp:</b>	18:49:25
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 990
RAM confirmation Number	3535
Deposit Account	502256
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	DPP4-5004-U_RCE.pdf	737837 0f319df1954d1bddcc35e53af2ce79938c3 12b8b7	no	3

## Warnings:

## Information:

2	Information Disclosure Statement (IDS) Filed	DPP4-5004-U_IDS_7-07-08.pdf	923692 371e1d0aab6825fca340c71ab0f2ae60 d2e64e1a	no	5
---	--	-----------------------------	--	----	---

## Warnings:

## Information:

3	Foreign Reference	WO03076414A2.pdf	1485846 391485d1571ea27e4ca65dead22cc91 2129e35b8	no	44
---	-------------------	------------------	---	----	----

## Warnings:

## Information:

4	Foreign Reference	WO05095381A1.pdf	8641200 18e26098db01f429d35fb7edacd44d5c 595e3198	no	170
---	-------------------	------------------	---	----	-----

## Warnings:

## Information:

5	NPL Documents	Banker-Modern_Pharmaceut ices-3ed_NY_1956_451-596 .pdf	159613 364cd38b711f79718741d895202d06bd 2cc4573e	no	3
---	---------------	--	--	----	---

## Warnings:

## Information:

6	NPL Documents	Cecil_Textbook_Medicine-B ennet_20thedition_v1-1004- 1010.pdf	890066 55564df7c370df608b60261eb87cb9638 b5e5a01	no	8
---	---------------	---	--	----	---

## Warnings:

## Information:

7	NPL Documents	Green-Expert_Opinion-Emer ging_Drugs-11-3_525-539-2 006.pdf	1067137 6830456ffbf9f56a461bfa2b071400ec16 662fc2	no	15
---	---------------	---	---	----	----

## Warnings:

## Information:

8	NPL Documents	Marcus_PubMed_Abstract_I ntervirology.pdf	71122 15cd22c52a9c5ae342aedce464d8201c ad68c008	no	1
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	van_Heeswijk_PubMed_Abs tract_Antivir_Ther.pdf	130270 43c13d88c91709d79327902b7d32af25 75e5c9ca	no	2
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	Vippagunta-Advanced_Drug _Delivery_Reviews-48_3-26 _2001.pdf	1931967 05066e8e9d08f4229710c0e0b60e5eb6 915ea9f	no	24
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	West-Sold_State_Chem_and _Applications-Wiley-NY-198 8_358-365.pdf	281436 b70e92a230227c97e78bbcea2f7ddd1d 65eae108	no	3
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	Wolff-Burger_Med_Chem-19 95_975-977.pdf	196445 99308ce576b1e8a5ab7a1c48a99f772a ea3f32e6	no	3
<b>Warnings:</b>					
<b>Information:</b>					
13	Miscellaneous Incoming Letter	DPP4-5004-McKesson_Stat ement_Signed.pdf	52499 6a5f0294ee5da3363107636dd1236e5d c0e9143b	no	2
<b>Warnings:</b>					
<b>Information:</b>					
14	Fee Worksheet (PTO-06)	fee-info.pdf	8291 36f467d750d437837fffc5758c63406632 76029a8	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>				16577421	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.